Research

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial 

Published in 2023 this randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial assessed for safety and tolerability of NMN on metabolic parameters that relate to aging. The results confirmed that orally administered NMN is absorbed  and quickly converted into NAD in human blood. 

NAD blood levels were increased in a dose dependent manner.  

References:

Yi L, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023 Feb;45(1):29-43. doi: 10.1007/s11357-022-00705-1. Epub 2022 Dec 8. PMID: 36482258; PMCID: PMC9735188. 

Ingredient in this research

Let’s keep in touch

Don’t worry we only send updates monthly on offers, product changes, and new opportunities for you.

Due to increased order volumes, some orders may experience shipping delays. Thank you for your patience and understanding.
×
Why Choose to Subscribe and Save?
  • Automatically re-order your favorite products on your schedule.
  • Easily change the products or shipping date for your upcoming Scheduled Orders.
  • If you decide a subscription is not for you, it can be cancelled after 2 renewals.